statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle...

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual...

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

/C O R R E C T I O N -- enGene Inc./ /C O R R E C T I O N -- enGene Inc./ PR Newswire BOSTON and MONTREAL, April 9, 2024 In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice...

/C O R R E C T I O N -- enGene Inc./

engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology...

engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress PR Newswire BOSTON and MONTREAL...

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

enGene To Present at the Leerink Partners Global Biopharma Conference enGene To Present at the Leerink Partners Global Biopharma Conference PR Newswire BOSTON and MONTREAL, March 5, 2024 BOSTON and...

enGene To Present at the Leerink Partners Global Biopharma Conference

enGene To Present at the Leerink Partners Global Biopharma Conference enGene To Present at the Leerink Partners Global Biopharma Conference Canada NewsWire BOSTON and MONTREAL, March 5, 2024 BOSTON...

enGene Holdings Inc. (NASDAQ:ENGN  Free Report)  Equities researchers at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of enGene in a note issued to investors on...

Analysts Offer Predictions for enGene Holdings Inc.'s Q1 2024 Earnings (NASDAQ:ENGN)

enGene Announces Oversubscribed $200 Million Private Placement Financing enGene Announces Oversubscribed $200 Million Private Placement Financing Canada NewsWire BOSTON and MONTREAL, Feb. 14, 2024...

enGene Announces Oversubscribed $200 Million Private Placement Financing

enGene Announces Oversubscribed $200 Million Private Placement Financing enGene Announces Oversubscribed $200 Million Private Placement Financing PR Newswire BOSTON and MONTREAL, Feb. 14, 2024...

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Watchers	917
52-Wk Low	$6.69
52-Wk High	$47.17

Volume	6,924.00
52-Wk High	$47.17
52-Wk Low	$6.69

ENGN enGene Holdings Inc

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community